INmune Bio (INMB) Earnings Call Presentation

Pipeline Highlights - XPro: Phase 2 Alzheimer's trial fully enrolled with top-line cognition results expected in June 2025[5], Phase I data showed a 222% increase in Contactin-2 and a 56% decrease in Neurogranin after 12 weeks of treatment[23] - CORDStrom: Completed blinded randomized trial in Recessive Dystrophic Epidermolysis Bullosa (RDEB) with US BLA submission planned for 2026[5], targeting a > $1 billion peak sales opportunity in the US, UK, and EU[50] - INKmune: Phase I dose escalation cohorts complete, with ongoing Phase 2 Metastatic Castrate Resistant Prostate Cancer (mCRPC) data readouts in 2025[5] XPro (Alzheimer's Disease) - TNF inhibitors reduce the risk of developing AD by 60% based on epidemiological studies of over 60 million cases[15] - Phase I results showed dose-dependent reduction of CSF biomarkers of neuroinflammation in AD patients[16] CORDStrom (RDEB) - CORDStrom is potentially the first systemic therapy for RDEB, with itch benefit as a key differentiating factor[50] - Mission EB trial: 30 pediatric patients with RDEB were treated in a double-blind, randomized, placebo-controlled cross-over design clinical trial[52, 56] INKmune (Cancer) - INKmune converts resting NK cells to cancer-killing memory-like NK cells[5, 73]